Asia Pacific Bladder Cancer Therapeutics Diagnostics Market by Products (Diagnostics and Therapeutics), Cancer Types (Squamous Cell Carcinoma, Adenocarcinoma, Transitional Cell Carcinoma, and Others), Diagnostics Types (Bladder Ultrasound, Cystoscopy, Urinalysis, and Others), Therapeutics Types (Immunotherapy, Chemotherapy, and Others), and Geography (China, India, South Korea, Japan, Australia, and Rest of Asia Pacific) – Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The Asia Pacific bladder cancer therapeutics diagnostics market size is expected to expand at a considerable CAGR of 4.8% during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of bladder cancer and the introduction of improved diagnostics and therapies in the market.
Bladder Cancer starts when the cells that make up the urinary bladder begin to proliferate out of control. More cancer cells can form a tumor and spread to other areas of the body as time goes on. It grows quickly and uncontrollably in the epithelial cells that line the urinary bladder. These malignant cells can even spread through the bladder's lining and into the muscular wall.
Bladder Cancer can hit anyone at any age but mostly affects people in their older age. It's usually detected initially when it's still curable and it's prone to reoccur, it's usually highly recommended to get expert advice after diagnosis. Blood in the urine is the most prevalent sign.
Market Trends, Drivers, Restraints, and Opportunities:
- Rising global bladder cancer market, due to growing knowledge of cancer and accessible treatment, rising healthcare spending, and rising smoking and tobacco usage are estimated to propel the market growth during the forecast period.
- Growing focus of key players on various expansion strategies including research and development activities and product approvals is projected to spur market expansion in the coming years.
- Technological advancements, novel treatments, enhanced health-care services, increased public awareness of cancer therapies, and rising healthcare spending are the main factors fueling the market expansion during the forecast period.
- Increasing usage of generic pharmaceuticals, an increasing number of medicines patent expirations, and expensive and improper diagnosis are some of the key challenges that can hamper the market expansion in the coming years.
- High costs of bladder cancer therapy, as well as the disease's asymptomatic nature, can impede market growth.
Scope of the Report
The report on the Asia Pacific bladder cancer therapeutics diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Bladder Cancer Therapeutics Diagnostics Market - Asia Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Products (Diagnostics and Therapeutics), Cancer Types (Squamous Cell Carcinoma, Adenocarcinoma, Transitional Cell Carcinoma, and Others), Diagnostics Types (Bladder Ultrasound, Cystoscopy, Urinalysis, and Others), and Therapeutics Types (Immunotherapy, Chemotherapy, and Others) |
|
Geographic Scope |
China, India, South Korea, Japan, Australia, and Rest of Asia Pacific |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Sanofi; Pfizer, Inc.; Novartis; Johnson & Johnson; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Endo Pharmaceuticals Inc.; Eli Lilly & Company; Bristol-Myers Squibb Company; and AstraZeneca Plc |
Asia Pacific Bladder Cancer Therapeutics Diagnostics Market Segment Insights
Therapeutics segment is expected to register at a significant pace
Based on products, the Asia Pacific bladder cancer therapeutics diagnostics market is bifurcated into diagnostics and therapeutics. The therapeutics segment is expected to hold a key share of the market during the forecast period owing to the condition of the patient and the stage of the bladder cancer, it is decided to do diagnostic or therapeutics, but both are inter-dependent to each other, it is very important to do the right diagnosis to do the right treatment, so both are necessary.
Transitional cell carcinoma segment is expected to expand at a significant pace
On the basis of cancer types, the market is segmented into squamous cell carcinoma, adenocarcinoma, transitional cell carcinoma, and others. The transitional cell carcinoma segment is expected to constitute a key share of the market in the coming years due to the high prevalence of bladder cancer cases in the market. Transitional cell carcinoma is otherwise known as urothelial carcinoma.
Bladder Ultrasound segment is anticipated to expand at a rapid CAGR
In terms of diagnostics types, the Asia Pacific bladder cancer therapeutics diagnostics market is segregated into bladder ultrasound, cystoscopy, urinalysis, and others. The bladder ultrasound segment is expected to account for a key share of the market during the forecast period owing to a sort of diagnostic instrument that utilizes sound waves to identify and diagnose cancer in the bladder. The rising prevalence of bladder cancer, as well as new gadgets being developed for cancer diagnostics, are projected to drive growth in this market. Due to its specificity, ultrasound is the most often used tool for identifying cancer in its early stages. As a result, demand for ultrasound devices is expected to drive the market during the forecast period.
Immunotherapy segment is expected to register at a considerable pace
Based on therapeutics types, the market is divided into immunotherapy, chemotherapy, and others. The immunotherapy segment is expected to represent a key share of the market in the coming years due to patients with bladder cancer can recover from new immunotherapies that lower recurrence rates and increase survival chances.
However, the chemotherapy segment is anticipated to expand at a rapid pace during the forecast period due to the most preferred type of treatment for urothelial cancer cells that are intended to stop or reduce their proliferation. It works throughout the body to kill and destroy cancer cells that have spread from the main tumor to other areas of the body.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Bladder Cancer Therapeutics Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Bladder Cancer Therapeutics Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Bladder Cancer Therapeutics Diagnostics Market - Supply Chain
4.5. Global Bladder Cancer Therapeutics Diagnostics Market Forecast
4.5.1. Bladder Cancer Therapeutics Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Bladder Cancer Therapeutics Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Bladder Cancer Therapeutics Diagnostics Market Absolute $ Opportunity
5. Global Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
6. North America Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
8. Europe Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Bladder Cancer Therapeutics Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Bladder Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Bladder Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Bladder Cancer Therapeutics Diagnostics Market: Market Share Analysis
11.2. Bladder Cancer Therapeutics Diagnostics Distributors and Customers
11.3. Bladder Cancer Therapeutics Diagnostics Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Sanofi Pfizer, Inc. Novartis Johnson & Johnson
The Asia Pacific bladder cancer therapeutics diagnostics market has been segmented on the basis of
Products
- Diagnostics
- Therapeutics
- Squamous Cell Carcinoma
- Adenocarcinoma
- Transitional Cell Carcinoma
- Others
- Bladder Ultrasound
- Cystoscopy
- Urinalysis
- Others
- Immunotherapy
- Chemotherapy
- Others
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
- Sanofi
- Pfizer, Inc.
- Novartis
- Johnson & Johnson
- GlaxoSmithKline
- F. Hoffmann-La Roche Ltd
- Endo Pharmaceuticals Inc.
- Eli Lilly & Company
- Bristol-Myers Squibb Company
- AstraZeneca Plc
Key players competing in the Asia Pacific bladder cancer therapeutics diagnostics market are Sanofi; Pfizer, Inc.; Novartis; Johnson & Johnson; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Endo Pharmaceuticals Inc.; Eli Lilly & Company; Bristol-Myers Squibb Company; and AstraZeneca Plc. Some of these players are adopting several market strategies including acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to increase their market shares.
Our Clients
Related Reports
Some other reports from this category!
